AAVantgarde Bio
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders. Its platform addresses a major limitation in traditional AAV (adeno-associated virus) gene delivery by enabling the packaging and delivery of large genes that exceed the usual vector capacity. The company’s two lead programs are AAVB-039, targeting Stargardt disease caused by ABCA4 mutations, and AAVB-081, for Usher syndrome type 1B (Usher 1B), affecting vision and hearing.
Tech Stack (12 technologies)
Frequently Asked Questions
What technologies does AAVantgarde Bio use?+
AAVantgarde Bio uses 12 technologies including Cookiebot, Google Tag Manager, Cookie Control.
What industry is AAVantgarde Bio in?+
AAVantgarde Bio operates in the Biotechnology industry.
Where is AAVantgarde Bio based?+
AAVantgarde Bio is headquartered in Italy.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026